Mizuho Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $90.00

On Thursday, Mizuho Securities issued a research report to clients and investors regarding Gilead Sciences (NASDAQGILD). The brokerage firm lowered its price target for the biopharmaceutical company from $101.00 to $90.00. This means that if the stock price reaches $90.00, it would represent a potential upside of 22.37% from its current price.

Gilead Sciences is a leading biopharmaceutical company that develops and commercializes innovative medicines for infectious diseases, cancer, and other serious conditions. The company's portfolio includes several blockbuster drugs such as Truvada, Harvoni, and Descovir.

Mizuho Securities has a "buy" rating on Gilead Sciences' stock, indicating that the brokerage firm believes the stock is undervalued and has potential for growth. However, the lower price target may indicate some concerns about the company's future performance or potential risks.

It's worth noting that Mizuho Securities is just one of many brokerage firms that provide research reports on Gilead Sciences and other publicly traded companies. These reports are often based on a variety of factors, including the company's financial performance, market trends, and competitive landscape. Investors should always consider multiple sources of information when making investment decisions.